Welcome to our dedicated page for Codexis SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Codexis, Inc. (CDXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Codexis is listed on The Nasdaq Global Select Market, and its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934, as reflected in its Form 8-K filings. These filings give investors insight into how Codexis reports its financial condition, strategic actions and material events related to its enzymatic solutions for therapeutics manufacturing and its ECO Synthesis® / ECO Synthesis™ platform.
Among the key documents available are Form 10-K annual reports and Form 10-Q quarterly reports, which typically contain detailed discussions of Codexis’s business, risk factors, financial statements and management’s analysis of results. For a company focused on enzyme technologies and oligonucleotide manufacturing, these filings can shed light on revenue contributions from its Pharma Biocatalysis business, investments in research and development for platforms such as CodeEvolver® and ECO Synthesis, and the financial impact of collaborations and licensing arrangements.
Codexis also files Form 8-K current reports to disclose material events. For example, an 8-K dated November 6, 2025 reports quarterly financial results and describes a workforce reduction aligned with an enhanced strategic focus on the ECO Synthesis platform, as well as executive leadership changes. Another 8-K dated August 13, 2025 announces financial results for the quarter ended June 30, 2025. These current reports help investors track significant developments between periodic filings.
On this page, users can also review Form 4 insider transaction reports and other relevant filings, where available, to understand equity awards and trading activity by directors and officers. Stock Titan enhances access to these documents with AI-powered summaries that explain key points from lengthy filings, highlight important sections in 10-K and 10-Q reports, and clarify the implications of 8-K disclosures. Real-time updates from EDGAR ensure that new Codexis filings, including those related to its enzyme-based manufacturing initiatives and organizational changes, are reflected promptly for further review and analysis.
Opaleye Management Inc., Opaleye, L.P. and James Silverman report a significant passive stake in Codexis, Inc. common stock. They beneficially own 6,789,738 shares, representing 7.52% of Codexis’s common stock, with shared voting and shared dispositive power over these shares and no sole voting or dispositive power.
The ownership percentage is based on 90,324,383 Codexis common shares outstanding as of 11/03/2025, as reported in the company’s 10-Q. The adviser also manages separate accounts that collectively hold 120,000 Codexis shares, with each account owning less than 5% of the class. The reporting persons certify the holdings were not acquired and are not held for the purpose of changing or influencing control of Codexis.
Codexis executive Kevin Norrett filed a Rule 144 notice to sell 1,745 shares of Codexis common stock through Morgan Stanley Smith Barney LLC on or about 01/16/2026. The filing reports an aggregate market value of 2914.32 for these shares, with 90324383 common shares outstanding. The shares to be sold were acquired as restricted stock from the issuer on 01/01/2026, with 1,745 securities acquired on that date. The notice also discloses that during the past three months, Norrett sold 6115 and 8 common shares on 01/07/2026 for gross proceeds of 10376.08 and 13.72, respectively. By signing, the seller represents that he is not aware of any undisclosed material adverse information about Codexis.
Aberdeen Group plc and abrdn Inc. filed an amended Schedule 13G reporting their beneficial ownership of 7,966,498 shares of Codexis, Inc. common stock, representing 8.82% of the class as of 12/31/2025. All of these shares are reported with shared voting and shared dispositive power, with no sole voting or dispositive authority.
The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Codexis. abrdn Inc. holds the position on behalf of underlying clients, with Aberdeen Group plc as the parent company and abrdn Holdings Limited as an intermediate holding company.
Codexis, Inc. CSO Stefan Lutz reported selling 4,685 shares of Codexis common stock on January 7, 2026 at a price of $1.6968 per share. According to the disclosure, this sale was made to cover tax liabilities arising from the vesting and release of restricted stock units held by him. After this transaction, Lutz beneficially owned 138,775 shares of Codexis common stock, which includes 41,633 restricted stock units, all held directly.
A holder of the issuer’s common stock has filed a notice of proposed sale under Rule 144 to sell 6,123 shares through Morgan Stanley Smith Barney Executive Financial Services on the NASDAQ, with an indicated aggregate market value of $10,409.10 and an approximate sale date of 01/07/2026.
The shares to be sold come from restricted stock units (RSUs) that vested and settled on 01/01/2026, when the holder acquired 17,450 shares as compensation for services rendered. The filing also notes that 90,324,383 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.
Opaleye Management Inc. filed an amended insider transaction report for its holdings in Codexis, Inc. This Form 4/A corrects a clerical error for a November 26, 2025 trade that was originally reported as a stock acquisition and is now correctly shown as a disposition of Codexis common shares.
The report lists multiple indirect sales of Codexis common stock, par value $0.001 per share, through Opaleye, L.P. and a separately managed account on November 26, November 28 and December 1, 2025. Share blocks were sold at weighted average prices of $1.7413, $1.75 and $1.6675 per share, with actual trade prices within ranges of $1.7316–$1.75699, $1.73–$1.7715 and $1.65–$1.7101 as described in the footnotes. After the December 1, 2025 transactions, the report shows 9,955,000 Codexis shares indirectly held via Opaleye, L.P. and 179,989 shares via a managed account.
Codexis, Inc. director-affiliated investor Opaleye Management Inc. filed an amended ownership report detailing recent sales of Codexis common stock made through affiliated investment vehicles.
On 11/07/2025, Opaleye L.P. sold 296,682 shares and a separately managed account sold 10,000 shares, each at a weighted average price of $1.6968 per share. Additional sales occurred on 11/10/2025 of 205,000 and 3,318 shares at a weighted average price of $1.7347, and on 11/11/2025 of 535,000 and 13,211 shares at a weighted average price of $1.7994.
Following these transactions, Opaleye L.P. is reported as indirectly holding 11,508,318 shares, and the managed account 223,461 shares of Codexis common stock. The amendment corrects a clerical error so that the 11/07/2025 trades are properly coded as dispositions rather than acquisitions, with no other changes.
Codexis, Inc. (CDXS) reported an insider transaction by a director on a Form 4. On 11/21/2025, the reporting person sold 8,952 shares of common stock in an open-market transaction coded as "S" (sale).
The weighted average sale price was $1.5626 per share, with individual trades executed between $1.55 and $1.615. Following this sale, the reporting person beneficially owns 138,951 shares, held directly, which includes 40,983 restricted stock units.
Codexis, Inc. (CDXS) reported an equity award to its President and CEO, Alison Moore, on Form 4. On 11/13/2025 she received 85,000 shares of common stock in the form of restricted stock units, at a stated price of $0. These units vest in three equal annual installments on each anniversary of the grant date, provided she remains employed.
On the same date she was also granted a stock option for 500,000 shares of common stock at an exercise price of $1.63 per share, expiring on 11/13/2035. The option vests as to 25% of the shares on the first anniversary of the grant date and 1/48th of the original total each month thereafter, conditioned on continued employment. Following these transactions, she beneficially owns 254,332 shares, including 145,208 restricted stock units.
Codexis, Inc. (CDXS) chief scientific officer reports equity holdings in a beneficial ownership statement dated 11/07/2025. The officer directly owns 143,460 shares of Codexis common stock, including 53,266 restricted stock units that each convert into one share upon vesting. In addition, the officer holds multiple stock options covering shares of common stock with exercise prices ranging from $3.05 to $26.16 and expirations between 2030 and 2035. Some options are already fully vested and exercisable, while others vest over time based on specified schedules tied to dates from 2021 through 2026.
FAQ
What is the current stock price of Codexis (CDXS)?
What is the market cap of Codexis (CDXS)?
